Evogene (EVGN) Change in Accured Expenses (2013 - 2026)
Evogene (EVGN) posted Change in Accured Expenses of $61000.0 for Q1 2026, up 303.33% sequentially from -$30000.0 in Q4 2025, and up 103.85% YoY from $29923.5 in Q1 2025.
Evogene (EVGN) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Evogene has reported Change in Accured Expenses for 14 years, with the latest figure at $61000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 103.85% year-over-year to $61000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$189000.0 (up 86.47% YoY) and the FY2025 annual result came in at -$756000.0, down 440.54% from the prior year.
- Change in Accured Expenses improved to $61000.0 in Q1 2026 per EVGN's latest filing, from -$30000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $634000.0 in Q4 2022 and troughed at -$1.6 million in Q1 2025.
- A 5-year average of -$95235.3 and a median of -$61000.0 in 2024 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses slumped 4457.14% in 2023, then surged 341.79% in 2024.
- Over 5 years, Change in Accured Expenses stood at $634000.0 in 2022, then slumped by 110.57% to -$67000.0 in 2023, then soared by 341.79% to $162000.0 in 2024, then plunged by 118.52% to -$30000.0 in 2025, then jumped by 303.33% to $61000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $61000.0, -$30000.0, and -$82000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 61,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,000.00 |
| Mar 31, 2026 | 61,000.00 |
| Dec 31, 2025 | -30,000.00 |
| Dec 31, 2025 | -30,000.00 |
| Sep 30, 2025 | -82,000.00 |
| Sep 30, 2025 | -82,000.00 |
| Jun 30, 2025 | -138,000.00 |
| Jun 30, 2025 | -138,000.00 |
| Mar 31, 2025 | -1.58 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Dec 31, 2024 | 162,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Sep 30, 2024 | 154,000.00 |
| Sep 30, 2024 | 154,000.00 |
| Jun 30, 2024 | -130,000.00 |
| Jun 30, 2024 | -130,000.00 |
| Mar 31, 2024 | -61,000.00 |
| Mar 31, 2024 | -61,000.00 |
| Dec 31, 2023 | -67,000.00 |
| Dec 31, 2023 | -67,000.00 |